一例接受度普利尤单抗治疗的嗜酸性粒细胞性皮炎患者完全康复。

A case of complete recovery in a hypereosinophilic dermatitis patient with dupilumab.

机构信息

Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Inflamm Res. 2023 Apr;72(4):875-878. doi: 10.1007/s00011-023-01715-1. Epub 2023 Mar 13.

DOI:10.1007/s00011-023-01715-1

PMID:36912915

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10010203/

Abstract

BACKGROUND

Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome (HES). Glucocorticoids are preferred for treatment but carry substantial side effect profiles. Symptoms of HED may recur after systemic glucocorticoid tapering. As an interleukin-4 receptor (IL-4Rα) monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), dupilumab might be an efficacious adjuvant therapy for HED.

METHOD

We report a young male diagnosed with HED who suffered from erythematous papules with pruritus for over five years. Once reducing the dosage of glucocorticoid was, his skin lesions relapsed.

RESULTS

After using dupilumab, the patient's condition significantly improved with the glucocorticoid dosing decreased successfully.

CONCLUSION

In conclusion, we report a new application of dupilumab in HED patients, especially with difficulties in reducing the glucocorticoid dose.

摘要

背景

嗜酸性粒细胞性皮炎（HED）是嗜酸性粒细胞增多综合征（HES）的一个亚型。糖皮质激素是首选治疗药物，但具有显著的副作用。HED 的症状可能在全身糖皮质激素逐渐减量后复发。作为一种针对白细胞介素-4（IL-4）和白细胞介素-13（IL-13）的白细胞介素-4 受体（IL-4Rα）单克隆抗体，度普利尤单抗可能是 HED 的一种有效的辅助治疗药物。